Treating early‐stage Hodgkin lymphoma in resource‐limited settings: InPOG‐HL‐15‐01 experience
- 22 July 2021
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 68 (10) , e29219
Abstract
Background: Hodgkin lymphoma (HL) in childhood is an eminently curable disease. Excellent outcomes can be achieved even in resource‐limited settings and increasingly, the focus is on limiting long‐term toxicity. Contemporary treatment incorporates a risk‐stratified, response‐adapted approach using multiagent chemotherapy with or without low‐dose radiotherapy (RT). Many developing countries continue to use ABVD (adriamycin, bleomycin, vinblastin, and dacarbazine)‐based regimen owing to limited acute toxicity, cost, and ease of delivery. We report outcomes of children with early‐stage HL using limited cycles of ABVD‐based treatment in the first prospective multicentric collaborative study from India InPOG‐HL‐15‐01.Methods: Children <18 years with biopsy‐proven HL were enrolled. Patients with stages I and IIA with or without bulky disease were classified as having early‐stage disease. Patients were planned to receive four cycles of ABVD subject to satisfactory early response assessment (ERA) scheduled after two cycles of chemotherapy. RT was limited to patients with bulky disease or those with suboptimal ERA.Results: Four hundred ten patients were enrolled over 30 months from 27 centers. One hundred thirty‐four were classified as having early‐stage disease. Fifty‐three (40%) of these had bulky disease. One hundred ten (83%) of this cohort achieved complete or very good partial ERA. Fifty‐four (40%) received RT. At a median of 52 months since diagnosis, 5‐year event‐free survival (EFS) and overall survival (OS) is 94% and 95.5%, respectively. Treatment‐related mortality and abandonment were <1%.Conclusion: Limited cycles of ABVD with RT to selected patients is a very effective option for patients with early‐stage disease in resource‐limited settings.Keywords
This publication has 23 references indexed in Scilit:
- Treatment of Children and Adolescents With Hodgkin Lymphoma Without Radiotherapy for Patients in Complete Remission After Chemotherapy: Final Results of the Multinational Trial GPOH-HD95Journal of Clinical Oncology, 2013
- Hodgkin Lymphoma in ChildrenJournal of Pediatric Hematology/Oncology, 2013
- Long-Term Results of CCG 5942: A Randomized Comparison of Chemotherapy With and Without Radiotherapy for Children With Hodgkin's Lymphoma—A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2012
- Response‐dependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: A report from the Children's Oncology GroupPediatric Blood & Cancer, 2012
- Procarbazine-Free OEPA-COPDAC Chemotherapy in Boys and Standard OPPA-COPP in Girls Have Comparable Effectiveness in Pediatric Hodgkin's Lymphoma: The GPOH-HD-2002 StudyJournal of Clinical Oncology, 2010
- Sézary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviorsBlood, 2010
- Final Results of a Prospective Clinical Trial With VAMP and Low-Dose Involved-Field Radiation for Children With Low-Risk Hodgkin's DiseaseJournal of Clinical Oncology, 2007
- Hodgkin’s lymphoma in Indian children: Prevalence and significance of Epstein–Barr virus detection in Hodgkin’s and Reed–Sternberg cellsEuropean Journal of Cancer, 2007
- Hodgkin's disease in Indian children: Outcome with chemotherapy alonePediatric Blood & Cancer, 2005
- Childhood Hodgkin disease treated with COPP/ABV hybrid chemotherapy: A progress reportMedical and Pediatric Oncology, 2002